Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 1/2012

01.03.2012 | Pharmacologic Therapy (WHW Tang, Section Editor)

Should We Start Prescribing Omega-3 Polyunsaturated Fatty Acids in Chronic Heart Failure?

verfasst von: Tara K. Jarreau, John H. Lee, Carl J. Lavie, Hector O. Ventura

Erschienen in: Current Heart Failure Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Chronic heart failure (HF) represents a significant health care burden. Over the past few decades, there have been considerable data supporting the benefits of omega-3 polyunsaturated fatty acids (PUFAs) on overall cardiovascular health. Reasons for the potential benefits of omega-3 PUFAs are multifactorial and not completely understood. It is likely that the culmination of multiple effects collectively help to prevent the development and slow the progression of chronic HF. A number of key epidemiologic and randomized trials have provided the basis of evidence in support of omega-3 PUFA supplementation in HF. This article reviews the benefits of omega-3 PUFAs and discusses the implications of recent trials. While the benefits seen in patients with chronic HF are modest at best, we believe the balance of evidence still favors the continuation of omega-3 PUFA supplementation in patients with chronic HF.
Literatur
1.
Heart Disease and Stroke Statistics--2011 Update: A Report From the American Heart Association. Circulation 2011, 123:e18-e209
2.
• Lee J, Jarreau T, Prasad A, et al.: Nutritional assessment in heart failure patients. Congestive Heart Failure 2011, 17:199–203. This is a well-written review paper on the benefits of nutritional supplementation, including omega-3 fatty acids, in the heart failure patient. PubMedCrossRef
3.
Wang C, Harris WS, Chung M, et al. n-3 Fatty acid from fish or fish-oil supplements, but not a-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84(1):5–17.PubMed
4.
Duda M, O’Shea K, Stanley W. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res. 2009;84:33–41.PubMedCrossRef
5.
Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 acids and cardiovascular disease. Circulation. 2002;106(21):2747–57.PubMedCrossRef
6.
Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids –a review. Nutr Metab Cardiovasc Dis. 2000;10:28–37.PubMed
7.
Lavie CJ, O’Keefe JH, Milani RV, et al. New data on the clinical impact of exercise training, fish oils, and statins in heart failure. Phys Sports Med. 2009;37(2):22–8.CrossRef
8.
•• Lavie CJ, Milani RV, Mehra MR, Ventura HO: Omega-3 polyunsaturated fatty acids and cardiovascular diseases-a fish tale with growing credibility. J Am Coll Cardiol 2009, 54:585–594. This is an excellent paper that summarizes the major clinical trials and provides expert insight on the benefits of omega-3 PUFAs. PubMedCrossRef
9.
London B, Albert C, Anderson ME, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation. 2007;116:e320–35.PubMedCrossRef
10.
Jacobson TA. Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease. Am J Clin Nutr. 2008;87:1981S–90S.PubMed
11.
Harris WS. Omega-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65:1645S–54S.PubMed
12.
Robinson JG. Antiatherosclerotic and antithrombotic effects of omega-3 fatty acids. Am J Cardiol. 2006;98:39i–49i.PubMedCrossRef
13.
Din JN, Harding SA, Valerio CJ, et al.: Dietary intervention with oil rich fish reduces platelet-monocyte aggregation in man. Atherosclerosis. 2007, E-pub ahead of print.
14.
Leaf A, Weber PC. Cardiovascular effects of omega-3 fatty acids. N Engl J Med. 1988;318:549–57.PubMedCrossRef
15.
Lortet S, Verger P. Alteration of cardiovascular function in trained rats fed with fish oil. Int J Sports Med. 1995;16:519–21.PubMedCrossRef
16.
Pepe S, McLennan PL. Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and postischemic recovery of contractile function. Circulation. 2002;105:2303–8.PubMedCrossRef
17.
Dallongeville J, Yarnell J, Ducimetiere P, et al. Fish consumption is associated with lower heart rates. Circulation. 2003;108:820–5.PubMedCrossRef
18.
Mozaffarian D, Geelen A, Brouwer I, et al. Effect of fish oil on heart rate-a meta-analysis of randomised controlled trials. Circulation. 2005;112:1945–52.PubMedCrossRef
19.
Peoples GE, McLennan PL, Howe PRC, Groeller H. Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharm. 2008;52(6):540–7.CrossRef
20.
Lee JH, O’Keefe JH, Lavie CJ, et al. Omega-3 fatty acids for cardioprotection. Mayo Clin Proc. 2008;83(3):324–32.PubMedCrossRef
21.
Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J Am Coll Cardiol. 2005;45:2015–21.PubMedCrossRef
22.
Yamagishi K, Nettleton JA, Folsom AR. Plasma fatty acid composition and incident heart failure in middle-aged adults: the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J. 2008;156:965–74.PubMedCrossRef
23.
Yamagishi K, Iso H, Date C, et al. Fish, omega-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women. J Am Coll Cardiol. 2008;52:988–96.PubMedCrossRef
24.
GISSI-Prevenzione Investigators, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999, 354 (9177):447 – 455.
25.
Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail. 2004;6:635–41.PubMed
26.
Pepe S, McLennan P. Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr. 1996;126:34–42.PubMed
27.
McLennan P, Abeywardena MY, Charnock JS. Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion. Am Heart J. 1988;116:709–17.PubMedCrossRef
28.
•• GISSI-HF Investigators: Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372 (9645):1223–1230. This is a major multicenter randomized clinical trial in heart failure patients. The results showed modest improvements in clinical outcomes and it is the first major trial to highlight the safety and tolerability to omega-3 PUFAs in conjunction with standard heart failure therapy.
29.
Witte KKA, Clark AL. Marine Polyunsaturated Fatty Acids in Heart Failure Are the theoretical benefits matched by clinical data? Pol Arch Med Wewn. 2009;119(3):162–8.PubMed
30.
Raitt MH, Conner WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators. JAMA. 2005;293:2884–91.PubMedCrossRef
31.
Brouwer IA, Zock PL, Camm AJ, et al. Effects of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators. JAMA. 2006;295:2613–9.PubMedCrossRef
32.
Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil omega-3 fatty acid intake. Circulation. 2005;112:2762–8.PubMedCrossRef
33.
Schwengel RH, Gottlieb SS, Fisher ML. Protein-energy malnutrition in patients with ischaemic and non-ischaemic dilated cardiomyopathy and congestive heart failure. Am J Cardiol. 1994;73:908–10.PubMedCrossRef
34.
Barber MD, Ross JA, Voss AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer. 1999;81:80–6.PubMedCrossRef
35.
Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improved body weight in severe heart failure. J Heart Lung Transplant. 2006;25(7):834–8.PubMedCrossRef
36.
Freeman LM, Rush JE, Kehayias JJ, et al. Nutritional alterations and the effect of fish oil supplementation in dogs with heart failure. J Vet Intern Med. 1998;12:440–8.PubMedCrossRef
37.
Lee JH, O’Keefe Jr JH. Lavie CJ, Harris WS: Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. Nat Rev Cardiol. 2009;6:753–8.PubMedCrossRef
38.
Lee JH, O’Keefe Jr JH, Lavie CJ, et al. Omega-3 Fatty Acids for Cardioprotection. Mayo Clin Proc. 2008;83(3):324–32.PubMedCrossRef
39.
Metadaten
Titel
Should We Start Prescribing Omega-3 Polyunsaturated Fatty Acids in Chronic Heart Failure?
verfasst von
Tara K. Jarreau
John H. Lee
Carl J. Lavie
Hector O. Ventura
Publikationsdatum
01.03.2012
Verlag
Current Science Inc.
Erschienen in
Current Heart Failure Reports / Ausgabe 1/2012
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-011-0073-5

Weitere Artikel der Ausgabe 1/2012

Current Heart Failure Reports 1/2012 Zur Ausgabe

Pharmacologic Therapy (W. H. Wilson Tang, Section Editor)

Pharmacologic Strategies to Target Oxidative Stress in Heart Failure

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

Surgical Approach to Mitral Regurgitation in Chronic Heart Failure: When Is It an Option?

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

Clinical Use of Telemonitoring in Chronic Heart Failure: Keeping up with the Times or Misuse of Time?

Nonpharmacologic Therapy: Surgery, Ventricular Assist Devices, Biventricular Pacing, and Exercise (AK Hasan, Section Editor)

Evaluating Heart Failure After Implantation of Mechanical Circulatory Support Devices

Pharmacologic Therapy (W. H. Wilson Tang, Section editor)

Medical Therapy for Acute Decompensated Heart Failure: What Recent Clinical Trials Have Taught Us About Diuretics and Vasodilators

Pharmacologic Therapy (W. H. Wilson Tang, Section editor)

Cardiac Gene Therapy: From Concept to Reality

Neu im Fachgebiet Kardiologie

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Weniger Extremitätenischämien mit dualer Plättchenhemmung

02.05.2024 Thrombozytenaggregationshemmer Nachrichten

Eine Behandlung mit Ticagrelor zusätzlich zu ASS kann das Risiko für Revaskularisierungen und Amputationen von Extremitäten bei Diabetikern mit stabiler KHK deutlich reduzieren, vor allem für solche mit PAVK. Dafür spricht eine Auswertung der Interventionsstudie THEMIS.

Beutel versus Maschine: Beste Beatmungstechnik bei Herzstillstand gesucht

02.05.2024 Kardiopulmonale Reanimation Nachrichten

Stehen die Chancen auf eine Rückkehr der Spontanzirkulation nach Herz-Kreislauf-Stillstand bei manueller oder maschineller Beatmung besser? Und unterscheidet sich das neurologische Outcome nach der Reanimation? Das belgische Herzstillstand-Register liefert die Daten für einen direkten Vergleich zwischen Beutel und Beatmungsgerät.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise